Bruker reports steady Q1 2026 revenue as bookings signal growth rebound

Bruker (NASDAQ:BRKR) reported first-quarter 2026 results that highlighted a resilient demand environment for high-end scientific instrumentation.

The Billerica, Massachusetts-based leader in life science research tools saw its revenue rise to $823.4 million, a 2.7% increase compared to the first quarter of 2025, even as the company navigated a 4.4% organic revenue decline during the period.

The quarter was defined by strong forward-looking indicators.

The Bruker Scientific Instruments (BSI) segment saw organic bookings grow in the high-single digits year-over-year.

Furthermore, Bruker maintained a book-to-bill ratio above 1.0x for the third consecutive quarter, suggesting a healthy backlog and strengthening demand for its advanced analytical technologies in the pharmaceutical and academic sectors.

On a GAAP basis, diluted earnings per share (EPS) for the first quarter was $0.02.

On a non-GAAP basis, which excludes acquisition-related costs and other specific items, diluted EPS stood at $0.31.

These results reflect the company’s continued investment in its "Project Accelerate 2.0" initiatives, focusing on high-growth areas such as proteomics, spatial biology, and semiconductor metrology.

Based on the quarterly performance and the strength of its current order book, Bruker reconfirmed its previous full-year 2026 guidance.

Total revenues is expected between $3.57 billion and $3.60 billion, representing 4% to 5% year-over-year growth.